[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.216.242. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 147
Citations 0
Comment & Response
March 2016

Inaccurate Reporting of Insulin Reimbursement

Author Affiliations
  • 1Senior Vice President, PhRMA, Washington, DC
JAMA Intern Med. 2016;176(3):408. doi:10.1001/jamainternmed.2015.8098

To the Editor In an article published in a recent issue of JAMA Internal Medicine, Luo et al1 fail to accurately characterize trends in prices for diabetes medicines in Medicaid by inaccurately suggesting that statutory rebates are capped at 23.1%, and such discounts could not be large enough to offset list price increases. In fact, Medicaid receives, on average, about a 60% discount2 because the 23.1% rebate the authors cite is a minimum, not a maximum; this is because Medicaid is guaranteed the best price on the commercial market and individual states often negotiate additional discounts.

First Page Preview View Large
First page PDF preview
First page PDF preview
×